What is PEG-MGF?

PEG-MGF is the pegylated form of mechano growth factor (MGF), also written as PEGylated mechano growth factor. It belongs to the IGF-1 (insulin-like growth factor-1) analogue class of research peptides, a category that also includes unmodified IGF-1 and related IGF-1 analogues [1]. The parent molecule, MGF, is a splice variant of the IGF-1 gene; pegylation refers to the attachment of polyethylene glycol chains, a chemical modification used in peptide research to alter circulation time. The evidence block used for this page does not supply a sequence, molecular formula, or molecular weight for PEG-MGF, so none are stated here.

The research literature in which PEG-MGF and its parent molecule appear centres on the IGF-1 receptor and the GH-IGF-1 axis, the endocrine signalling system that links growth hormone release to IGF-1-mediated tissue effects [1].

Research Studies

PEG-MGF and the IGF-1 analogue class in GH-IGF-1 axis research

PEG-MGF sits within the IGF-1 analogue group described in reviews of performance-enhancing peptides marketed as research compounds. That review places IGF-1 analogues alongside GHRH analogues (sermorelin, tesamorelin, CJC-1295 with and without DAC), growth hormone secretagogues (GHRP-2, GHRP-6, hexarelin, ipamorelin), and the GH fragment AOD9604 (hGH 176-191) as agents encountered in clinical practice and in online self-administration protocols [1]. The review frames these compounds collectively as unregulated peptides intended to modulate the GH-IGF-1 axis [1]. This is a classification and landscape description, not a report of a controlled trial of PEG-MGF itself.

PEG-MGF and pegylation as a research modification

Pegylation is a recognised strategy in peptide and protein research for modifying how a molecule behaves after administration. The clearest pegylation example in the evidence block is a clinical study of PEG-somatropin (pegylated recombinant human growth hormone, PEG-rhGH) in children with Turner syndrome, which was designed to explore optimal dosing, preliminarily evaluate safety and efficacy, and provide evidence for a Phase 3 trial [8]. That study concerns PEG-rhGH, not PEG-MGF, and the population was paediatric patients with Turner syndrome. It is cited here only to illustrate that pegylation of a GH-axis peptide has been studied clinically in a specific patient group; no equivalent clinical study of PEG-MGF appears in the evidence.

PEG-MGF and the limits of the available evidence

The evidence block does not contain an animal study, an in vitro study, or a human trial of PEG-MGF specifically. The only direct mention of the IGF-1 analogue class is the landscape review, which describes the category and notes that these peptides are unregulated and are encountered in self-administration settings [1]. Any statement that PEG-MGF produces a tissue effect, a repair response, or a measurable outcome in a named model is not supported by the evidence provided and is therefore not made on this page.

PEG-MGF compared with other GH-IGF-1 axis research peptides

The table below sets out the compound classes named in the review and the corresponding evidence status within the evidence block. It is a comparison of categories, not of measured effects.

PEG-MGF and the GH-IGF-1 axis in clinical research

The GH-IGF-1 axis is the subject of active clinical research, but the trials captured in the evidence block address other compounds and other populations. These include trials of trontinemab in participants with early symptomatic Alzheimer's disease (mild cognitive impairment to mild dementia due to Alzheimer's disease) [2], a pre-screening study assessing potential eligibility for Roche interventional Alzheimer's disease studies [3], and the EVOKE and EVOKE Plus studies of semaglutide in people with early Alzheimer's disease, each lasting up to 173 weeks with 17 clinic visits and 1 phone call [4][5]. None of these trials involve PEG-MGF, and none report outcomes for the IGF-1 analogue class.

PEG-MGF and unrelated comparator trials in the evidence block

Several studies in the evidence block concern cardiovascular and cerebrovascular questions rather than the GH-IGF-1 axis. One study was conducted to improve knowledge about the epidemiology of lipoprotein(a) in patients with established cardiovascular disease [6]. The THALES study investigated whether ticagrelor and ASA were more effective than placebo and ASA in preventing new stroke events in patients with acute stroke or transient ischaemic attack [7]. These are included here only to make clear what the evidence block does and does not contain; they provide no information about PEG-MGF.

PEG-MGF and the regulatory status of research peptides

The landscape review states that performance-enhancing drugs marketed as research compounds include unregulated peptides intended to modulate the GH-IGF-1 axis, and that these agents are commonly encountered in clinical practice and online self-administration protocols [1]. That characterisation applies to the class as a whole, including IGF-1 analogues. It is a statement about marketing and regulatory status, not about efficacy or safety in any model.

PEG-MGF and what a laboratory-grade specification covers

For a research peptide, the specification that matters to a laboratory is identity, purity, and the form supplied, not a clinical claim. The evidence block does not provide a certificate of analysis, a purity figure, or a sequence for PEG-MGF, and none are asserted here. Researchers working with the compound should rely on the documentation supplied with the specific lot rather than on any general description of the class.

If you are reading this for personal health reasons

This material is sold for laboratory research only, and we do not provide dosing or medical guidance. Anyone considering a compound for themselves should speak to a licensed clinician. Nothing on this page is a recommendation for human use.

Sources

• [1] The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. https://europepmc.org/article/PMC/PMC13322892
• [2] A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease. https://clinicaltrials.gov/study/NCT07170150
• [3] Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies. https://clinicaltrials.gov/study/NCT07177352
• [4] A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE). https://clinicaltrials.gov/study/NCT04777396
• [5] A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus). https://clinicaltrials.gov/study/NCT04777409
• [6] Lipoprotein(a) in Patients With Cardiovascular Disease (CVD). https://clinicaltrials.gov/study/NCT03887520
• [7] THALES - Acute STroke or Transient IscHaemic Attack Treated With TicAgreLor and ASA for PrEvention of Stroke and Death. https://clinicaltrials.gov/study/NCT03354429
• [8] A Study of PEG-somatropin Injection to Treat Children of Turner Syndrome. https://clinicaltrials.gov/study/NCT03189160